Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYADNASDAQ:FBRXNASDAQ:VINCNASDAQ:ZYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsFBRXForte Biosciences$6.28-1.6%$6.61$4.11▼$28.68$41.34M2.82153,294 shs25,145 shsVINCVincerx Pharma$0.06+4.4%$0.40$0.05▼$17.17$288K1.8423,947 shs91,665 shsZYNEZynerba Pharmaceuticals$1.30$1.30$0.25▼$1.40$70.12M1.32515,333 shsN/A12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad Oncology0.00%0.00%0.00%0.00%0.00%FBRXForte Biosciences-1.57%-5.71%+19.62%-43.47%+20,973.83%VINCVincerx Pharma+4.36%0.00%-79.25%-95.90%-99.66%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AFBRXForte Biosciences3.3187 of 5 stars3.55.00.00.02.21.71.3VINCVincerx Pharma2.4459 of 5 stars3.54.00.00.00.01.71.3ZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad Oncology 0.00N/AN/AN/AFBRXForte Biosciences 3.00Buy$32.50417.52% UpsideVINCVincerx Pharma 3.00Buy$40.0072,627.27% UpsideZYNEZynerba Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZYNE, VINC, FBRX, and CYAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $61.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad Oncology$110K144.65N/AN/A$0.26 per share2.31FBRXForte BiosciencesN/AN/AN/AN/A$24.30 per shareN/AVINCVincerx PharmaN/AN/AN/AN/A$10.50 per shareN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/A$1.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/AFBRXForte Biosciences-$31.48M-$16.29N/AN/AN/AN/A-151.43%-118.92%N/AVINCVincerx Pharma-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%5/13/2025 (Estimated)ZYNEZynerba Pharmaceuticals-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyad OncologyN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad Oncology0.263.59N/AFBRXForte BiosciencesN/A2.062.06VINCVincerx PharmaN/A2.172.17ZYNEZynerba PharmaceuticalsN/A3.433.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyad OncologyN/AFBRXForte Biosciences77.63%VINCVincerx Pharma44.02%ZYNEZynerba Pharmaceuticals11.23%Insider OwnershipCompanyInsider OwnershipCYADCelyad Oncology0.94%FBRXForte Biosciences3.10%VINCVincerx Pharma15.60%ZYNEZynerba Pharmaceuticals13.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableFBRXForte Biosciences56.58 million6.20 millionOptionableVINCVincerx Pharma605.23 million1.89 millionNot OptionableZYNEZynerba Pharmaceuticals2553.94 million46.91 millionOptionableZYNE, VINC, FBRX, and CYAD HeadlinesRecent News About These CompaniesUS Penny Stocks To Watch In October 2024October 28, 2024 | uk.finance.yahoo.comDiscover 3 US Penny Stocks With Market Caps Over $70MOctober 24, 2024 | uk.finance.yahoo.comAtea Pharmaceuticals Leads The Charge In US Penny Stocks SpotlightOctober 22, 2024 | uk.finance.yahoo.comGW Pharma's cannabis-derived epilepsy drug approved in EUOctober 7, 2024 | pharmaphorum.comFragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery PartnersJuly 31, 2024 | globenewswire.comHarmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsOctober 31, 2023 | finance.yahoo.comWhy Shares of Harmony Bioscience Are Falling on FridayOctober 13, 2023 | fool.comNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesOctober 11, 2023 | markets.businessinsider.comHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEOctober 11, 2023 | finance.yahoo.comH.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)October 10, 2023 | knoxdaily.comAnalysts: ZYNE stock price target of $1.25 in 12 monthsOctober 5, 2023 | knoxdaily.comImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsOctober 4, 2023 | finance.yahoo.comExamining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)October 2, 2023 | knoxdaily.com20 Countries With Highest Rate of EpilepsySeptember 29, 2023 | finance.yahoo.comZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023September 29, 2023 | finance.yahoo.comHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealSeptember 27, 2023 | bizjournals.comZynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the RiseSeptember 25, 2023 | knoxdaily.comZynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. WainwrightSeptember 20, 2023 | knoxdaily.comNegative sentiment towards ZYNE reflected in surge in short interestSeptember 15, 2023 | knoxdaily.comInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncSeptember 14, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYNE, VINC, FBRX, and CYAD Company DescriptionsCelyad Oncology NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Forte Biosciences NASDAQ:FBRX$6.28 -0.10 (-1.57%) Closing price 05/12/2025 03:58 PM EasternExtended Trading$6.30 +0.02 (+0.40%) As of 05/12/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Vincerx Pharma NASDAQ:VINC$0.06 +0.00 (+4.36%) As of 05/12/2025 03:58 PM EasternVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Zynerba Pharmaceuticals NASDAQ:ZYNEZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
